Altamira Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Thomas Meyer(1.2%)
Altamira Therapeutics | 424B4: Prospectus
Altamira Therapeutics | EFFECT: Others
Altamira Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)
Altamira Therapeutics | 424B5: Prospectus
Altamira Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)
Altamira Therapeutics | CORRESP: CORRESP
Altamira Therapeutics | UPLOAD: Others
Altamira Therapeutics | F-3: Registration statement for specified transactions by certain foreign private issuers
Altamira Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Altamira Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Altamira Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Altamira Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Altamira Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)
Altamira Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Altamira Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Altamira Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)
Altamira Therapeutics | 6-K/A: Report of foreign private issuer (related to financial reporting)
Altamira Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Altamira Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
No Data